Last reviewed · How we verify
SU011248; Capecitabine
At a glance
| Generic name | SU011248; Capecitabine |
|---|---|
| Also known as | Sutent, sunitinib, SU11248, Xeloda |
| Sponsor | Pfizer |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Pan Tumor Rollover Study (PHASE2)
- Sunitinib and Capecitabine for First Line Colon Cancer (PHASE2)
- Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial (PHASE1)
- A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer (PHASE1)
- Participatory Research for Fine-tuning of a 2.0 System to Optimise Home Management of Oral Cancer Therapies. (NA)
- Capecitabine With or Without Sunitinib Malate as First-Line Therapy in Treating Patients With Metastatic Cancer of the Esophagus or Gastroesophageal Junction (PHASE2)
- Sunitinib Malate and Capecitabine in Treating Patients With Unresectable or Metastatic Liver Cancer (PHASE2)
- Brain Mets - Capecitabine Plus Sunitinib and WBRT (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |